This study evaluates the significance of serum interleukin-22 levels in patients with chronic lymphocytic leukemia (CLL) and its relationship with disease characteristics. The findings indicate that IL-22 levels are significantly higher in CLL patients compared to healthy controls and correlate positively with ZAP-70 expression, suggesting that IL-22 could serve as a diagnostic and prognostic marker in CLL management.